Stem cell therapy developer Athersys (NASDAQ:ATHX) reported positive interim results from a phase 1 clinical trial in patients with leukemia or similar blood cancers. The trial showed that the company’s MultiStem technology was well tolerated at all dose levels and also suggested that the technology may reduce the incidence of severe graft-versus-host disease, according to […]
Stem cell therapy developer Athersys (NASDAQ:ATHX) plans to begin the first clinical study of its MultiStem technology in stroke patients by the end of the year. The planned double-blind, placebo-controlled study could involve as many as 150 patients, CEO Gil Van Bokkelen said in a conference call with analysts and investors after announcing the Cleveland-based […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Stem cell therapy developer Athersys (NASDAQ:ATHX) and partner Pfizer (NYSE:PFE) have begun enrolling patients in a phase 2 clinical trial for inflammatory bowel disease.
Stem cell company Athersys Inc. (NASDAQ:ATHX) has reached an agreement to sell about $13 million of its shares to unidentified private investors.
Stem cell company Athersys completed a study showing its technology could hold therapeutic benefits in treating spinal cord injuries. Researchers found that administering Athersys' MultiStem technology to rodents with spinal injuries reduced inflammation and promoted the regrowth of neurons.
Athersys Inc. (NASDAQ:ATHX) has completed patient enrollment in the single-dose portion of a clinical trial that's treating blood cancer patients with the company's stem cell therapy.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Floyd Loop, the former Cleveland Clinic CEO credited with turning around the once-struggling hospital, has resigned from the board of stem cell company Athersys Inc. (NASDAQ:ATHX).
A former custodian with stem cell developer Athersys (NASDAQ:ATHX) has been accused by federal prosecutors of running a stock scam that bilked would-be investors out of $340,000 over six years.
LeMaitre Vascular Inc. (NASDAQ:LMAT) picked up Angiotech Pharmaceuticals Inc.’s (NASDAQ:ANPI) Lifespan vascular graft business for $2.8 million and spiked a distribution deal Angiotech had with former Lifespan owner Edwards Lifesciences Corp. (NYSE:EW). Burlington, Massachusetts-based LeMaitre said it paid a multiple of 1.8 times the Lifespan revenues from the last 12 months for the vascular prosthesis, […]
Athersys Inc. (NASDAQ: ATHX) has received the regulatory thumbs-up to begin a Phase 2 clinical trial of its MultiStem stem cell treatment for inflammatory bowel disease.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Athersys Inc. CEO Gil Van Bokkelen has been elected chairman of the The Alliance for Regenerative Medicine.
Athersys Inc. reported more positive results from an ongoing Phase 1 clinical trial of its adult stem cell therapy for the treatment of heart-attack patients.
Athersys Inc.'s stem cell therapy has been granted orphan drug designation by the Food and Drug Administration for graft-versus-host disease.
Athersys Inc.'s (NASDAQ:ATHX) stem cell therapy showed positive results in an early preclinical investigation of its effects in treating traumatic brain injury.
An FDA panel's decision to reject the obesity drug lorcaserin shouldn't affect Athersys Inc.'s (NASDAQ: ATHX) development of a similar drug, the Cleveland-based company's chief executive said.